Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.
April ArmstrongAndrew BlauveltEric L SimpsonCatherine H SmithPedro HerranzYoko KataokaSeong Jun SeoSilvia M FerrucciJingdong ChaoZhen ChenAna B RossiBrad ShumelPaul TomondyPublished in: Dermatology and therapy (2021)
ClinicalTrials.gov Identifier NCT01949311; EudraCT 2013-001449-15.
Keyphrases